Neurotech Pharmaceuticals, Inc. is a privately held biotech company located in Cumberland, Rhode Island. Neurotech has spent years developing the science, technology, team and manufacturing behind NT-501. As a result of a unique partnership and clear direction, we are focused on bringing a long-term treatment to Macular Telangiectasia (MacTel) patients.  Our team is focused on bringing to market this treatment designed to slow the progression of MacTel and the vision impairments it causes in patients who don't have another treatment option. Our goal is to help these patients sustain their quality of life.

Biotechnology

Neurotech Pharmaceuticals, Inc.

Richard Small

Paul Brannelly

Lovisa Selander

Brett Aguiar

Matthew Fera

Andrew Vitorino Ormonde

Jacob Patterson Esq.

Arne Nystuen

Patricia Davis (Patty)

Terry McCurren

Derek Barnett

Sean K.

Scott Bertolami

The Quality and Compliance Team at Neurotech Pharmaceuticals, Inc. ensures that all operations, from research and development to manufacturing and distribution, adhere to regulatory standards and internal policies. This team is responsible for maintaining the highest quality of product integrity and compliance with industry regulations to guarantee that NT-501 meets the stringent requirements needed for treating Macular Telangiectasia (MacTel) patients effectively and safely.

Quality and Compliance Team

Quality Control

Clinical and Market Access Team

Quality and Compliance Team

About

Team members

Other teams at Neurotech Pharmaceuticals, Inc.

Quality Control

Clinical and Market Access Team